Power Versus Temperature Controlled Ablation for Treatment of VT
Key facts
- Who runs it
- University Hospitals Coventry and Warwickshire NHS Trust
- Where
- United Kingdom2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 61 people enrolled
- Started
- 26 Sept 2022
- Ended
- 21 Nov 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Temperature controlled DiamondTemp (DT) ablation catheter
- Tacticath/Tactiflex (TF) ablation catheter
- Record updated
- 14 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- ≥ 18 years of age to give informed consent specific to national legal requirements
- Subject with 1 of the following:; Symptomatic VT (despite optimal medical therapy), 3 or more episodes of VT within 24 h (VT storm); At least 3 episodes of VT requiring anti-tachycardia pacing (ATP); At least one appropriate ICD shock
- Referred for VT ablation by Consultant Electrophysiologist
- Subject discussed at cardiac EP MDT
- Suitable candidate for intra-cardiac mapping and ablation of arrhythmia
- Subject agrees to comply with study procedures and be available for routine follow up visits for at least 12 months after enrolment
- Subject is willing and able to provide written consent
Who cannot take part
- Sepsis, active systemic infection or fever (>100.5 F/38 C) within a week prior to the ablation procedure
- Known allergies or intolerance to anticoagulant and antiplatelet therapies to be used in conjunction with the study or contrast sensitivity that can't be adequately pre-treated prior to the ablation procedure
- Enrolment in a concurrent clinical study that in the judgement of the investigator would increase risk to the subject or deem the subject inappropriate to participate in the study
- Coagulopathy, bleeding diathesis or suspected pro-coagulant state
- Significant restrictive or obstructive pulmonary disease or chronic respiratory condition
- Renal failure requiring dialysis or renal compromise that in the investigators judgement would increase risk to the subject or deem the subject inappropriate to participate in the study
- BMI >40kg/m2
- Presence of intramural thrombus, tumour or abnormality that precludes vascular access, catheter introduction or manipulations
- Positive pregnancy test results for female subjects of childbearing or potential or breast feeding
- Significant GI bleed
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Ventricular Tachycardia (VT) is a life threatening heart rhythm that comes from the bottom chambers of the heart (the ventricles) and is a leading cause of sudden cardiac death.
Read full original descriptionShow less
The majority of patients that are at risk of VT or suffer a cardiac arrest will have an Internal Cardiac Defibrillator (ICD) in situ to treat the abnormal heart rhythm. The ICD can deliver a painful shock to restore normal heart rhythm but importantly does not treat the underlying cause. Current treatment for the prevention of recurrent VT include catheter ablation (CA) or medication. Long-term results with global 12 month VT-free survival rates with CA are around 50%.
The trial is to compare 2 different types of ablation catheter that are used to cauterise small areas of unhealthy tissue within the heart that are responsible for VT: Diamond Temp (DT) and Tacticath/Tactiflex (TF). Our hypothesis is that the DT ablation catheter will provide comparable efficacy and safety for the treatment of VT as the current industry gold standard (TF).
The 2 groups in the trial
- Temperature controlled DiamondTemp (DT) ablation catheterOther group
Intervention arm
- Power controlled Tacticath/Tactiflex ablation catheterOther group
Control arm
Treatment: Tacticath/Tactiflex (TF) ablation catheter
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomised Control Trial of Power Versus Temperature-controlled Irrigated Radiofrequency Ablation for the Treatment of Ventricular Tachycardia (VT)
- Record updated
- 14 April 2026